MEI Pharma CEO Daniel Gold's 2019 pay falls 38% to $1.9M
MEI Pharma reports 2019 executive compensation
By ExecPay News
Published: October 23, 2019
MEI Pharma reported fiscal year 2019 executive compensation information on October 23, 2019.
In 2019, four MEI Pharma executives received on average a compensation package of $1.2M, a 24% decrease compared to previous year.
Daniel P. Gold, Chief Executive Officer, received $1.9M in total, which decreased by 38% compared to 2018. 51.48% of Gold's compensation, or $954.6K, was in option awards. Gold also received $289.8K in non-equity incentive plan and $610K in salary.
David M. Urso, Chief Operating Officer, received a compensation package of $1.3M, which increased by 5% compared to previous year. 53.52% of the compensation package, or $700.1K, was in option awards.
Brian G. Drazba, Chief Financial Officer, earned $842.6K in 2019, a 17% decrease compared to previous year.
Robert D. Mass, Chief Medical Officer, received $674.3K in 2019, which decreases by 23% compared to 2018.
MEI Pharma's fiscal year ends on June 30.